DYRK1A and metastatic malignant neoplasm: Regarding the pharmacological effects of DYRK1A inhibition, the intended tissue may vary from inside the brain as in the case of neurodegenerative diseases and CNS cancers such as GBM, via the pancreas for β-cell proliferation, to the general circulation for metastatic cancers in the lungs and intestines.